CytomX

Probody™ Therapeutic Targeting PD-1 Provides Preclinical Anti-tumor Efficacy While Minimizing Induction of Autoimmunity as a Single Agent and in Combination with CTLA-4 Blockade

Kimberly A. Tipton, Kenneth R. Wong, Victoria Singson, Chihunt Wong, Chanty Chan, Yuanhui Huang, Shouchun Liu, Jennifer H. Richardson, W. Michael Kavanaugh, James W. West and Bryan A. Irving. Poster presented at SITC 2016, November 9-13, National Harbor, Maryland.

PD-1 Probody™ Therapeutic Anti-tumor Efficacy and Protection Against Autoimmunity in Preclinical Models

Kimberly A. Tipton, Chanty Chan, Kenneth R. Wong, Victoria Singson, Laura P. Serwer, Yuanhui Huang, Shouchun Liu, Jennifer H. Richardson, W. Michael Kavanaugh, Bryan A. Irving and James W. West. Poster presented at AACR 2016, April 16-20, New Orleans, Louisiana.

PROCLAIM-CX-072: Analysis of Patients With Advanced Solid Tumors Receiving Long-Term Treatment With CX-072, a PD-L1 PROBODY Therapeutic, as a Single Agent or in Combination With Ipilimumab

Fiona Thistlethwaite, Aung Naing, Marta Gil-Martin, Patricia LoRusso, Manreet Randhawa, Ferry Albert Louis Maria Eskens, Rachel E. Sanborn, Nataliya Uboha, Daniel Cho, Alexander I. Spira, Igor Bondarenko, Ruth Plummer, Javier Garcia-Corbacho, Ivan Victoria, Javier Lavernia, Ignacio Melero, E.G.E. DeVries, Will Garner, Hendrik-Tobias Arkenau, Johanna Bendell. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Evidence of Intratumoral Localization, Activation, and Immunomodulatory Effect of CX-072, a PROBODY Therapeutic Targeting PD-L1, in a Phase 1/2 Trial

Susan K. Lyman, Aung Naing, Ivan A. Zein, Yuanbin Ru, Bruce Howng, Michael B. Winter, Olga Vasiljeva, Will Garner, Beiyao Zheng, Mark Stroh, Hong Lu, Jennifer Richardson, W. Michael Kavanaugh, Luc R. Desnoyers. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Preliminary Population Pharmacokinetics Supports Phase 2 Dose Selection for Masked Anti–PD-L1 Antibody CX-072

Mark Stroh, Michelle Green, B.L. Millard, Will Garner, Hong Lu, Jennifer Richardson, Lawrence Lu, Alison Hannah. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

CX-072, a PD-L1 Probody Therapeutic, as Monotherapy in Patients With Advanced Solid Tumors: Preliminary Results of PROCLAIM-CX-072

Aung Naing, Fiona Thistlethwaite, Alexander Spira, Javier Garcia-Corbacho, Manreet Randhawa, Ferry ALM Eskens, Greg Durm, Nataliya Uboha, Omid Hamid, Anthony El-Khoueiry, Vanessa Huels, Will Garner, Beverly Benson, Hendrik-Tobias Arkenau, Patricia LoRusso. Poster presented at ASCO 2019, May 31-June 4, Chicago, Illinois.

PROCLAIM-CX-072: Monotherapy for Advanced Triple-Negative Breast Cancer With Skin Metastases in a Phase 1/2a Trial of the PD-L1 Probody Therapeutic CX-072

Sylvia Adams, Erika Hamilton, Patrick A. Ott, Daniel Cho, Kevin Kalinsky, Patricia LoRusso, Matthias Will, Vanessa Huels, Beverly Benson, Carmen Murias, Hendrik-Tobias Arkenau. Poster presented at the 41^st Annual San Antonio Breast Cancer Symposium, San Antonio, Texas.

Preliminary Evidence of Intratumoral Activation and Immunomodulatory Effect of CX-072, a Probody Therapeutic Antibody Prodrug Targeting PD-L1, in a Phase 1/2 Trial

Susan K. Lyman, Judi Gordon, Amy DuPage, Preeti Pramanik, Bruce Howng, Ivan A. Zein, Michael B. Winter, Irina K. Popova, Olga Vasiljeva, James Jones, Ken Wong, Victoria Singson, Jennifer Richardson, Beiyao Zheng, Mark Stroh, Lori Carman, Vanessa Huels, Karen Autio, Valentina Boni, Daniel Cho, Javier Garcia-Corbacho, Iván Victoria Ruiz, Omid Hamid, Nataliya Uboha, Elisabeth de Vries, Anthony El-Khoueiry, Alexander Spira, Rachel E. Sanborn, Fiona Thistlethwaite, Hendrik-Tobias Arkenau, Johanna Bendell, Patrick A. Ott, Naiyer Rizvi, Matthias Will, W. Michael Kavanaugh, Aung Naing, Luc R. Desnoyers. Poster presented at SITC 2018, November 7-11, Washington, D.C.

Preliminary Results of PROCLAIM-CX-072: The First-in-Human, Dose-Finding Trial of PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients With Advanced Solid Tumors

Valentina Boni, Javier Garcia-Corbacho, Patrick A. Ott, Daniel Cho, Karen A. Autio, Nataliya Uboha, Alexander I. Spira, Rachel Humphrey, Matthias Will, Aung Naing, Fiona Thistlethwaite, Elisabeth de Vries, Hendrik-Tobias Arkenau. Poster presented at ESMO 2018, October 19-23, Munich, Germany.

Preliminary Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial Evaluating the PD-L1 Probody Therapeutic CX-072 in Combination With Ipilimumab in Patients With Advanced Solid Tumors

Ruth Plummer, Rachel E. Sanborn, Elisabeth de Vries, Patricia LoRusso,Hendrik-Tobias Arkenau, Nataliya Uboha, Jerzy Wydmanski, Mary Josephine Fidler, Valentina Boni, Javier Garcia-Corbacho, Rachel Humphrey, Matthias Will, Karen A. Autio, Anthony El-Khoueiry, C. Willemien Menke-van der Houven van Oordt, Fiona Thistlethwaite. Poster presented at ESMO 2018, October 19-23, Munich, Germany.

Preliminary Interim Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic (Pb-Tx) CX-072 in Combination with Ipilimumab (ipi) in Patients (pts) with Advanced Solid Tumors

Rachel E. Sanborn, Catharina Wilhelmina Menke, Karen A. Autio, Hendrik-Tobias Arkenau, Javier Garcia Corbacho, Patricia LoRusso, Elizabeth Ruth Plummer, Nataliya Volodymyrivna Uboha, Morganna Louise Freeman, Jerzy Wydmanski, Vanessa Huels, Beiyao Zheng, Matthias Will, Rachel W. Humphrey, Fiona Thistlethwaite, Elisabeth G.E. de Vries, Anthony B. El-Khoueiry. Poster presented at ASCO 2018, June 1-5, Chicago, Illinois.

Preliminary Results of the First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial of the PD-L1 Probody Therapeutic CX-072 as Monotherapy in Patients (pts) with Advanced Solid Tumors

Karen A. Autio, Hendrik-Tobias Arkenau, Bert H. O’Neil, Johanna C. Bendell, Anthony El-Khoueiry, James Strauss, Amy Weise, Nataliya Volodymyrivna Uboha, Naiyer A. Rizvi, Beiyao Zheng, Luc Desnoyers, Mark Stroh, Lori Carman, Rachel W. Humphrey, Matthias Will, Valentina Boni, Alexander I. Spira, Aung Naing. Poster presented at ASCO 2018, June 1-5, Chicago, Illinois.

A PD-L1-targeted Probody™ Therapeutic Provides Anti-Tumor Efficacy While Minimizing Induction of Systemic Autoimmunity in Preclinical Studies

Chihunt Wong, Li Mei, Kenneth R. Wong, Jennifer Razo, Chanty Chan, Elizabeth Menendez, Shouchun Liu, Olga Vasiljeva, Jennifer H. Richardson, James W. West, W. Michael Kavanaugh, Bryan A. Irving. Poster presented at CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference 2015, September 16-19, New York, New York.

PROCLAIM-CX-072: A First-in-Human Trial to Assess Tolerability of the Protease-Activatable Anti–PD-L1 Probody™ CX-072 in Solid Tumors and Lymphomas

Alexander I. Spira, Mark R. Middleton, Aung Naing, Karen A. Autio, John J. Nemunaitis, Johanna C. Bendell, Michael Gordon, Rachel W. Humphrey, Chihunt Wong, Naiyer A. Rizvi. Poster presented at ASCO 2017, June 2-6, Chicago, Illinois.

The First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial to Assess the Antitumor Activity and Tolerability of the Probody™ Therapeutic CX-072 as Monotherapy and in Combination With Ipilimumab or Vemurafenib in Solid Advanced Tumors and Lymphomas

Valentina Boni, Javier Garcia-Corbacho, Jaime Feliu, Jerzy Wydmanski, Zsolt Horvath, Igor Bondarenko, Bryan Irving, Matthias Will, Elisabeth de Vries, Fiona Thistlethwaite. Poster presented at ESMO 2017, September 8-12, Madrid, Spain.

Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor

Marcia Belvin Ph.D. Presented at World ADC, October 16-19, 2023, San Diego, California.

Tailoring the Selection of Target, Payload, and Tumor Type to Maximize the Therapeutic Index of Conditionally Activated ADCs

Marcia Belvin, SVP, Head of Research

Harnessing the Power of CytomX’s Probody^® Technology to Drug the Undruggable

Alison L. Hannah, MD. Presented at the World ADC Digital Conference, September 15-18, 2020.

Utilizing Probody^® Technology to Develop Therapeutics to Undruggable Targets

Bob Liu, Ph.D. Presented at the World ADC Digital Conference, September 15-18, 2020.

Development of a Probody Drug Conjugate (PDC) Targeting CD71 for the Treatment of Cancer

Presented at 10th Annual World Antibody Drug Conjugate Conference. London, United Kingdom March 4, 2020
Luc Desnoyers, Ph.D.

CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients with Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase

Melissa Johnson, Jordi Rodon Ahnert, Nehal Lakhani, Rachel E. Sanborn, Anthony El-Khoueiry, Navid Hafez, Hirva Mamdani, Valentina Boni, Henry Castro, Alison L. Hannah, Alexander Spira. Presented at the IASLC 2020 World Conference on Lung Cancer Singapore virtual meeting, January 28-31, 2021.

CX-2029, a PROBODY Drug Conjugate Targeting CD71 (Transferrin Receptor): Results From a First-in-Human study (PROCLAIM-CX-2029) in Patients With Advanced Cancer

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Thang Ho, Rachel Li, Jana Waldes, Alexander I. Spira. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Preclinical Development of a Probody™ Drug Conjugate (PDC) Targeting CD71 for the Treatment of Multiple Cancers

Shweta Singh, Amy DuPage, Annie Yang Weaver, Michael Krimm, Clayton White, Jason Sagert ,Yuanhui Huang, Linnea Diep, Shouchun Liu, Jennifer Richardson, W. Michael Kavanaugh, Jonathan A. Terrett, Luc R. Desnoyers. Poster presented at AACR 2016, April 16-20, New Orleans, Louisiana.

Developing a CD71-Targeting Probody™ Drug Conjugate (PDC) for Activity in Multiple Solid Tumor and Lymphoma Models and for Tolerability in Non-human Primates

Shweta Singh, Laura Serwer, Niharika Chauhan, Amy DuPage, Michael Krimm, Ken Wong, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Fritz Buchanan, Matthew Ravn, Rob Leanna, Ilaria Badagnani, Tracy Henriques, Shouchun Liu, Luc Desnoyers, Claus Krebber, Sridhar Viswanathan, Jennifer Richardson, Susan Morgan-Lappe and W. Michael Kavanaugh. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets 2017, October 26-30, Philadelphia, Pennsylvania.

A Multi-Analyte HPLC-MS/MS Approach to Assessing Exposure of a Probody™ Drug Conjugate in Preclinical Studies

Laura P. Serwer, Shweta Singh, Claus Krebber, Shouchun Liu, Niharika Chauhan, Robert Leanna, Hong Lu, Ilaria Badagnani, Tracy Henriques, Susan Morgan-Lappe, William Mylott Jr., Sridhar Viswanathan, Jennifer H. Richardson, W. Michael Kavanaugh. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets 2017, October 26-30, Philadelphia, Pennsylvania.

Results of a phase 2 study of praluzatamab ravtansine (CX-2009) in patients with advanced breast cancer (ABC)

Kathy Miller, Sara M. Tolaney, Leisha Emens, Sung-Bae Kim, Erika Hamilton, Cristina Saura, Lucia Sanz, Valentina Boni, Filipa Lynce, Juan M. Cejalvo, Jennifer A. Crozier, Shirley Wang, Shannon Tsai, Hojjat Bazzazi, Hirdesh Uppal, Alison Hannah, Sara Hurvitz. Poster presented at the San Antonio Breast Cancer Symposium^®, December 6-10, 2022.

Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of the Probody^® Therapeutic (Pb-Tx) Praluzatamab Ravtansine (CX-2009) in Metastatic HR-Positive/HER2-Negative Breast Cancer (mHR+/HER2− BC) and of CX-2009 as Monotherapy and in Combination Therapy With Pacmilimab (CX-072) in Metastatic Triple-Negative Breast Cancer (TNBC)

Kathy D. Miller, Leisha A. Emens, Sara M. Tolaney, Sara A. Hurvitz, Erika Hamilton, Virginia Paton, Alison Hannah, Valentina Boni. Poster presented at the San Antonio Breast Cancer Symposium^®, December 8-11, 2020.

Intratumoral Activation and Phase 1/2 Clinical Activity of Praluzatamab Ravtansine (CX-2009), a Probody^® Drug Conjugate (PDC) Targeting CD166

Liu J, Zein IA, Dang T, Lyman SK, Wang S, Spira A, Uboha N, LoRusso P, Fidler MJ, Meric-Bernstam F, Arkenau T, Nagasaka M, Desnoyers LR, Kavanaugh WM, Paton VE, Hannah AL, Boni V. Poster presented at the San Antonio Breast Cancer Symposium^®, December 8-11, 2020.

CX-2009, a CD166-Directed PROBODY Drug Conjugate (PDC): Results From the First-in-Human Study in Patients With Advanced Cancer Including Breast Cancer

Valentina Boni, Howard Burris, Joyce Liu, Alexander Spira, Hendrik-Tobias Arkenau, Mary Josephine Fidler, Lee Rosen, Randy F. Sweis, Nataliya Uboha, Rachel E. Sanborn, Bert O’Neil, James Harding, Patricia LoRusso, Amy Weise, Javier Garcia-Corbacho, Ivan Victoria, Mark Stroh, Rachel Li, Alison Hannah, Ginny Paton, Funda Meric-Bernstam. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Preliminary Clinical Pharmacokinetics and Dose-Response to Support a Phase 2 Dose Selection for CX-2009: A Masked PROBODY Drug Conjugate to CD166

Mark Stroh, Rachel Li, Hong Lu, Russ Wada, Jennifer Richardson, Amy Peterson. Poster presented at the ASCO20 Virtual Scientific Program, May 29-31, 2020.

Preliminary Results of PROCLAIM-CX-2009, a First-in-Human, Dose-Finding Study of the Probody™ Drug Conjugate CX-2009 in Patients With Advanced Solid Tumors

Funda Meric-Bernstam, Valentia Boni, Alexander Spira, Rachel E. Sanborn, Hendrik-Tobias Arkenau, Randy F. Sweis, Howard Burris, Rui Li, Pratigya Gautam, Sreeni Yalamanchili, Matthias Will, Joyce F. Liu, James J. Harding. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia.

A Probody™ Drug Conjugate Targeting CD166 (ALCAM) Enhances Preclinical Antitumor Activity of a Probody Therapeutic Targeting PD-1

Erwan Le Scolan, Tiffany Tse, Michael Krimm, Will Garner, Hikmat Assi, Jennifer Razo, Laurie Wong, Kenneth R. Wong, Victoria Singson, Jennifer Leong, Linnea Diep, Jennifer H. Richardson, Siew Schleyer, Dylan Daniel, Marcia Belvin, W. Michael Kavanaugh. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia

CD166-DM4 Probody™ Drug Conjugate (CX-2009) Treatment of 198 Patient -derived Xenograft Models (PDX) in a Mouse Clinical Trial Format

Bob Y. Liu, Joel Shen, Matthias Will, Sreeni Yalamanchili, Judi Ford-Gordon, Mark Stroh, Jennifer Richardson, Annie Yang-Weaver, Luc R. Desnoyers, Marcia Belvin, W. Michael Kavanaugh, Siew Schleyer. Poster presented at AACR 2019, March 29-April 3, Atlanta, Georgia.

Development of a Probody™ Drug Conjugate (PDC) Targeting CD166 for the Treatment of Multiple Cancers

Annie Yang Weaver, Shweta Singh, Amy DuPage, Jason Sagert, Jeanne Flandez, Elizabeth Menendez, Judi Ford, Michael Krimm, Stephen Moore, Margaret Nguyen, Andrew Jang, Eric Brecht, Yuanhui Huang, Linnea Diep, Nicole Lapuyade, Tereza Sputova, James West, Olga Vasiljeva, Shouchun Liu, Jennifer Richardson, W. Michael Kavanaugh, Jonathan A. Terrett, Luc R. Desnoyers. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015, November 5-9, Boston, Massachusetts.

PROCLAIM-CX-2009: A First-in-Human Trial to Evaluate CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors

Javier Garcia-Corbacho, Alexander Spira, Valentina Boni, Jaime Feliu, Mark Middleton, Howard Burris, Annie Yang Weaver, Matthias Will, James Harding, Funda Meric-Bernstam, Volker Heinemann. Poster presented at ESMO 2017, September 8-12, Madrid, Spain.

Leveraging Conditional Activation to Localize Antibody Drug Conjugates to the Tumor

Marcia Belvin Ph.D. Presented at World ADC, October 16-19, 2023, San Diego, California.

Tailoring the Selection of Target, Payload, and Tumor Type to Maximize the Therapeutic Index of Conditionally Activated ADCs

Marcia Belvin, SVP, Head of Research

CX-2043, an EpCAM-Targeting Probody Drug Conjugate, Demonstrates Anti -Tumor Activity with a Favorable Safety Profile in Preclinical Models

Bob Y. Liu, Joel Shen, Wendy Yu, Chaoran Jing, Sharmi Saha, Vangipuram Rangan, Jennifer Richardson, Yimao Liu, Steven Boule, Jacquelynn Lucas, Olga Ab, Stuart Hicks, W. Michael Kavanaugh, Siew Schleyer, Marcia Belvin. Poster presented at the 32nd EORTC-NCI-AACR Symposium, October 24-25, 2020.

EGFR-CD3 Bispecific Probody™ Therapeutic Induces Tumor Regressions and Increases Maximum Tolerated Dose > 60 fold in Preclinical Studies

Leila M. Boustany, Sherry L. La Porte, Laurie Wong, Clayton W. White, Linnea Diep, Yuanhui Huang, Shouchun Liu, Jennifer H. Richardson, W. Michael Kavanaugh, Bryan A. Irving. Poster presented at AACR-NCI-EORTC International Conference on Molecular Targets 2017, October 26-30, Philadelphia, Pennsylvania.

Conditionally activated IFNa induces an inflammatory tumor microenvironment in preclinical models and increases efficacy in combination with checkpoint blockade

Benjamin Povinelli, Kamaljeet Kaur, Alexey Berezhnoy, Hsin Wang, Na Cai, Nicole Lapuyade, Carol LePage, Michael Winter, Olga Vasiljeva, Madan Paidhungat, Vangipuram Rangan, Erwan Le Scolan, Leila Boustany, Marcia Belvin and Dylan Daniel. Presented at SITC 2023, November 1-5, 2023, San Diego, CA.

Designing Conditionally Activated Probody® Cytokines to Localize Antitumor Activity to Cancers

Dylan Daniel, Ph.D., Presented at the American Association of Immunologists Annual Meeting, May 13, 2023.

CX-801, Conditionally Activatable Interferon-alpha 2b Improves Tolerability and Exhibits Preferential Activity in Tumors

Alexey Berezhnoy, Ph.D., Presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), November, 8th, 2022.

Probody-Interferon-alpha 2b Combines Antitumor Activity with Improved Tolerability

Alexey Berezhnoy, Ph.D., Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022, April 11th, 2022.

Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity: Preclinical characterization of a dual-masked IFN-a2b

Alexey Berezhnoy, Ph.D., Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021), November 13th, 2021.

Conditional Cytokine Therapeutics for Tumor-Selective Biological Activity Preclinical characterization of a dual-masked IFNα-2b

Erwan Le Scolan, Ph.D., Presented at the Cytokine-Based Cancer Immunotherapies Summit, March 24th, 2021.

Praluzatamab Ravtansine, a CD166-Targeting Antibody– Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

Boni V, Fidler MJ, Arkenau HT, et al. Praluzatamab ravtansine, a CD166-targeting antibody-drug conjugate, in patients with advanced solid tumors: an open-label phase 1/2 trial [published online ahead of print, 2022 Feb 14]. Clin Cancer Res. 2022;clincanres.3656.2021. doi:10.1158/1078-0432.CCR-21-3656

Conditional PD-1/PD-L1 Probody therapeutics induce comparable antitumor immunity but reduced systemic toxicity compared with traditional anti–PD 1/PD-L1 agents

Assi HH, Wong C, Tipton KA, et.al. Cancer Immunol Res. October 11 2021. DOI: 10.1158/2326-6066.CIR-21-0031

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Sanborn RE, Hamid O, de Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002446. doi: 10.1136/jitc-2021-002446

CX-072 (pacmilimab), a Probody^®️ PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Naing A, Thistlethwaite F, De Vries EG, et al. Journal for ImmunoTherapy of Cancer 2021;9:e002447. doi: 10.1136/jitc-2021-002447

First-in-human study of the biodistribution and pharmacokinetics of ⁸⁹Zr-CX-072, a novel immunoPET tracer based on an anti-PD-L1 probody

Kist de Ruijter L, Hooiveld-Noeken JS, Giesen D, et al. [published online ahead of print, 2021 Jul 12]. Clin Cancer Res. 2021;clincanres.0453.2021. doi:10.1158/1078-0432.CCR-21-0453

Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic

Etxeberria I, Bolaños E, Teijeira A, et al. Proc Natl Acad Sci U S A. 2021;118(26):e2025930118. doi:10.1073/pnas.2025930118

Phase 1, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies

Johnson M, El-Khoueiry A, Hafez N, et. al. Clin Cancer Res. June 7, 2021; doi: 10.1158/1078-0432.CCR-21-0194.

Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology

Autio KA, Boni V, Humphrey RW, Naing A. Clin Cancer Res. 2020 26(5): 984-989. doi:10.1158/1078-0432.CCR-19-1457.

Probody Therapeutic Design of ⁸⁹Zr-CX-072 Promotes Accumulation in PD-L1-Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Giesen D, Broer LN, Lub-de Hooge MN, et al. Clin Cancer Res. January 17, 2020; doi: 10.1158/1078-0432.CCR-19-3137.

The Tumor Targeting Performance of Anti-CD166 Probody Drug Conjugate CX-2009 and its Parental Derivatives as Monitored by ⁸⁹Zr-immuno-PET in Xenograft Bearing Mice

Chomet M, Schreurs M, Nguyen M, et al. Theranostics. 2020; 10(13): 5815-5828. doi:10.7150/thno.44334.

QSP Model of a Masked Tumor-Activated Antibody Video Abstract

Video accompanying Stroh et al. “Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody.” CPT Pharmacometrics Syst. Pharmacol. (2019). doi: 10.1002/psp4.12448

Antibody prodrugs for cancer

Expert Opinion on Biological Therapy; Kavanaugh, W. Michael; Published Online December 2019.

The Multifaceted Roles of Tumor-Associated Proteases and Harnessing their Activity for Prodrug Activation

Biol. Chem. (2019) 400(8): 965–977.

Nonclinical Development of Probody Drug Conjugates

Richardson, J. (2019, September) Nonclinical Development of Probody Drug Conjugates. Presented at the Charles River 25^th Annual Biotech Symposium: Biotechnology-Derived Therapeutics Perspectives on Nonclinical Development. Carlsbad, CA.

Designing In and Around Tolerability Considerations for Immunotherapy Combinations

Clinical Pharmacology & Therapeutics; Stroh, M.; April 2018.

Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody

CPT: Pharmacometrics and Systems Pharmacology; Stroh, M., et al; May 2019.

Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates

Lin J., Sagert J. (2018) Targeting Drug Conjugates to the Tumor Microenvironment: Probody Drug Conjugates. In: Damelin M. (ed). Innovations for Next-Generation Antibody-Drug Conjugates. Cancer Drug Discovery and Development. Humana Press, Cham.

In vivo imaging of protease activity by Probody therapeutic activation

Biochimie; Vasiljeva O, et al; November 2015.

Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index

Science Translational Medicine; Desnoyers, L., Vasiljeva, O., Richardson, J., Yang, A., Menendez, E., Liang, T.,… Lowman, H.; October 2013

Imaging a functional tumorigenic biomarker in the transformed epithelium

Proceedings of the National Academy of Sciences USA; LeBeau, A. et al; January 2013

Identification of protease exosite-interacting peptides that enhance substrate cleavage kinetics

Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases

Journal of Controlled Release; Erster, O. et al; August 2012

Emerging principles in protease-based drug discovery

Nature Reviews Drug Discovery; Drag, M. et al; September 2010

Evolutionary optimization of peptide substrates for proteases that exhibit rapid hydrolysis kinetics

Biotechnology and Bioengineering; Boulware K, et al; June 2010.

Tumor detection by imaging proteolytic activity

Cancer Research; Darragh M, et al; February 2010.

Methods for the proteomic identification of protease substrates

Current Opinion in Chemical Biology; Agard N, et al; December 2009.

The urokinase plasminogen activator system: a target for anti-cancer therapy

Current Cancer Drug Targets; Ulisse S, et al; February 2009.

Matrix metalloproteases: underutilized targets for drug discovery

Journal of Drug Targeting; Vartak D, et al; January 2007.

Matriptase and its putative role in cancer

Protease specificity determination by using cellular libraries of peptide substrates (CLiPS)

Proceedings of the National Academy of Sciences USA; Boulware K, et al; May 2006.

Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands

Protein Science; Rice J, et al; April 2006.

Proteases, extracellular matrix, and cancer: a workshop of the path B study section

American Journal of Pathology; DeClerck Y, et al; April 2004.